Filter by: patients
What is Zerit?

ZeritĀ® is a brand name for stavudine, a reverse transcriptase inhibitor (nucleoside) antiretroviral drug used for the treatment of HIV infection in combination with other antiretroviral agents. Read more...Click to read more below

Reported Purpose & Efficacy

Reasons and Efficacy
Purpose # of patients
# of patients with evaluations Efficacy
Major
Moderate
Slight
None
Can’t tell
HIV (Human Immunodeficiency Virus) 11 4 Efficacy_major Efficacy_moderate

See all 5 patients currently taking Zerit

Mouse over the table for more information

Reported Side Effects

Side effects as an overall problem

Severe
2
Moderate
1
Mild
0
None
1

Commonly reported side effects, conditions, and hospitalizations associated with Zerit

Diarrhea 2
Neuropathic pain in feet and legs 1
Cramps in stomach 1

Reported Dosages

  2 daily 30 mg daily 40 mg daily 80 mg daily
  1 Number of Patients: 1 1 Number of Patients: 1 1 Number of Patients: 1 2 Number of Patients: 2  

Reported Stop Reasons

Why Patients Stopped Taking Zerit (multiple reasons could be selected)
Reason # Patients Percentage of patients
Side effects too severe 4   Side effects too severe: 50%
Doctor's advice 3   Doctor's advice: 38%
Other 2   Other: 25%

See all 8 patients who’ve stopped taking Zerit

Currently Taking Zerit

A bar graph

0-1 month 1-3 months 3-6 months 6 months-1year 1-2 years 2 years or more
0
0
0
0
0

Stopped Taking Zerit

A bar graph

0-1 month 1-3 months 3-6 months 6 months-1year 1-2 years 2 years or more
0
0
0

Reported Adherence, Burden & Cost See details from patient evaluations

Adherence

Taking treatment as prescribed

Adherence of Zerit

Always
4 100%
Usually
0 0%
Sometimes
0 0%
Never
0 0%

Burden

Difficulty being on treatment

Burden of Zerit

Very
0 0%
Somewhat
2 50%
A little
0 0%
Not at all
2 50%

Cost

Paid out of pocket

Cost of Zerit

$200+
0 0%
$100-199
0 0%
$50-99
0 0%
$25-49
0 0%
< $25
1 100%

See more information, including instructions, precautions, side effects, and interactions.

Report created on February 11, 2012.